Teleflex (NYSE:TFX) Price Target Cut to $200.00 by Analysts at Truist Financial

Teleflex (NYSE:TFX) had its price target lowered by Truist Financial from $227.00 to $200.00 in a report published on Wednesday,Benzinga reports. The firm currently has a hold rating on the medical technology company’s stock.

Several other brokerages have also recently weighed in on TFX. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Mizuho decreased their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research report on Monday. Finally, Royal Bank of Canada decreased their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Teleflex presently has an average rating of “Moderate Buy” and a consensus price target of $255.14.

Teleflex Stock Down 3.2 %

TFX stock opened at $172.66 on Wednesday. The company has a market capitalization of $8.02 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 1.84 and a beta of 1.16. Teleflex has a 12 month low of $172.45 and a 12 month high of $256.85. The firm’s fifty day simple moving average is $204.80 and its 200-day simple moving average is $219.97. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.38 by $0.11. The company had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.64 earnings per share. As a group, equities research analysts forecast that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Friday, November 15th. Teleflex’s dividend payout ratio (DPR) is 27.04%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund grew its holdings in shares of Teleflex by 1.2% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock valued at $846,000 after purchasing an additional 46 shares during the period. Cromwell Holdings LLC grew its stake in shares of Teleflex by 59.0% in the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after buying an additional 49 shares during the period. Crossmark Global Holdings Inc. increased its holdings in shares of Teleflex by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock worth $584,000 after buying an additional 53 shares during the last quarter. Apollon Wealth Management LLC raised its position in shares of Teleflex by 3.7% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock valued at $377,000 after buying an additional 55 shares during the period. Finally, SRS Capital Advisors Inc. lifted its holdings in Teleflex by 0.3% in the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock valued at $4,844,000 after acquiring an additional 60 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.